carmustine has been researched along with Body Weight in 22 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chemotherapy with dacarbazine, carmustine, and cisplatin produces a modest objective response rate in melanoma." | 9.07 | Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin. ( Losada, R; Meelu, MA; Nathanson, L, 1994) |
| "Sodium cyanate injected IP at a dose level of 200 or 250 mg/kg caused a 90% or greater inhibition of the incorporation of [3H]thymidine into DNA of B16 melanoma transplanted SC in mice." | 7.67 | Effects of sodium cyanate in mice bearing B16 melanoma. ( Carpenter, L; Hill, GJ; Hill, HZ; Lea, MA; Luke, A; Martinson, CF; Velazquez, O, 1986) |
| " Inter-individual differences in the pharmacokinetic disposition of high-dose chemotherapy may explain variability in both response and toxicity." | 6.70 | Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| "Chemotherapy with dacarbazine, carmustine, and cisplatin produces a modest objective response rate in melanoma." | 5.07 | Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin. ( Losada, R; Meelu, MA; Nathanson, L, 1994) |
| "Poorly-differentiated human brain glioma xenografted nude mice were treated with carmustine(1, 3-bis-(2-chloroethyl)-1-nitrosourea, BCNU) and sodium phenylbutyrate (SPB)." | 3.71 | [Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug]. ( Dong, J; Huang, Q; Lan, Q; Shi, MG; Sun, ZF, 2002) |
| "Sodium cyanate injected IP at a dose level of 200 or 250 mg/kg caused a 90% or greater inhibition of the incorporation of [3H]thymidine into DNA of B16 melanoma transplanted SC in mice." | 3.67 | Effects of sodium cyanate in mice bearing B16 melanoma. ( Carpenter, L; Hill, GJ; Hill, HZ; Lea, MA; Luke, A; Martinson, CF; Velazquez, O, 1986) |
| " Inter-individual differences in the pharmacokinetic disposition of high-dose chemotherapy may explain variability in both response and toxicity." | 2.70 | Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| "Melphalan dose was used as surrogate for the entire regimen." | 1.35 | Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. ( Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF, 2008) |
| " A dose-response relationship for BCNU was observed (hazard ratio 0." | 1.30 | Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. ( Brem, H; Burger, PC; Piantadosi, S; Sipos, EP; Tyler, B, 1997) |
| "The SF-767 brain tumors were extremely responsive to BE-4-4-4-4 alone (3 of 8 complete regressions after 2 cycles); however, the growth of the U-87 MG brain tumor was only slightly inhibited by BE-4-4-4-4 treatment." | 1.29 | Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. ( Basu, HS; Casero, RA; Dolan, ME; Feuerstein, BG; Fleig, MJ; Luk, GD; Marton, LJ, 1994) |
| "Amiodarone (AM) is an effective antidysrhythmic agent, restricted in use by the development of adverse effects, including potentially fatal AM-induced pulmonary toxicity (AIPT)." | 1.29 | Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. ( Brien, JF; Leeder, RG; Mandin, CC; Massey, TE; Rafeiro, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 9 (40.91) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costa, LJ | 1 |
| Micallef, IN | 1 |
| Inwards, DJ | 1 |
| Johnston, PB | 1 |
| Porrata, LF | 1 |
| Litzow, MR | 1 |
| Ansell, SM | 1 |
| Abushamaa, AM | 1 |
| Sporn, TA | 1 |
| Folz, RJ | 1 |
| Karsila-Tenovuo, S | 1 |
| Jahnukainen, K | 1 |
| Peltomäki, T | 1 |
| Salmi, TT | 1 |
| Rönning, O | 1 |
| Shi, MG | 1 |
| Huang, Q | 1 |
| Dong, J | 1 |
| Sun, ZF | 1 |
| Lan, Q | 1 |
| Hansen, RJ | 1 |
| Nagasubramanian, R | 1 |
| Delaney, SM | 1 |
| Cherian, MM | 1 |
| Lin, S | 1 |
| Kogan, SC | 1 |
| Dolan, ME | 2 |
| Tannock, IF | 1 |
| Aas, AT | 2 |
| Brun, A | 2 |
| Pero, RW | 2 |
| Salford, LG | 2 |
| Fleig, MJ | 1 |
| Feuerstein, BG | 1 |
| Basu, HS | 1 |
| Luk, GD | 1 |
| Casero, RA | 1 |
| Marton, LJ | 1 |
| Takenaga, M | 1 |
| Igarashi, R | 1 |
| Tsuji, H | 1 |
| Mizushima, Y | 1 |
| Nathanson, L | 1 |
| Meelu, MA | 1 |
| Losada, R | 1 |
| Gerson, SL | 1 |
| Zborowska, E | 1 |
| Norton, K | 1 |
| Gordon, NH | 1 |
| Willson, JK | 1 |
| Wedge, SR | 1 |
| Newlands, ES | 1 |
| Leeder, RG | 1 |
| Rafeiro, E | 1 |
| Brien, JF | 1 |
| Mandin, CC | 1 |
| Massey, TE | 1 |
| Sipos, EP | 1 |
| Tyler, B | 1 |
| Piantadosi, S | 1 |
| Burger, PC | 1 |
| Brem, H | 1 |
| Mackintosh, CA | 1 |
| Pegg, AE | 1 |
| Petros, WP | 1 |
| Broadwater, G | 1 |
| Berry, D | 1 |
| Jones, RB | 1 |
| Vredenburgh, JJ | 1 |
| Gilbert, CJ | 1 |
| Gibbs, JP | 1 |
| Colvin, OM | 1 |
| Peters, WP | 1 |
| Bhide, S | 1 |
| Habs, M | 1 |
| Reinbold, H | 1 |
| Schmähl, D | 1 |
| Hill, KE | 1 |
| Taylor, MA | 1 |
| Ziegler, DM | 1 |
| Burk, RF | 1 |
| Rawson, CL | 1 |
| Larson, RE | 1 |
| Lea, MA | 1 |
| Luke, A | 1 |
| Velazquez, O | 1 |
| Carpenter, L | 1 |
| Martinson, CF | 1 |
| Hill, HZ | 1 |
| Hill, GJ | 1 |
| Thompson, DJ | 1 |
| Molello, JA | 1 |
| Strebing, RJ | 1 |
| Dyke, IL | 1 |
| Robinson, VB | 1 |
2 trials available for carmustine and Body Weight
| Article | Year |
|---|---|
Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexi | 1994 |
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Weight; Breast Neoplas | 2002 |
20 other studies available for carmustine and Body Weight
| Article | Year |
|---|---|
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Dis | 2008 |
Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen.
Topics: Amifostine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Blood Cell Count; Body Weight; | 2002 |
Induced leukemia and antineoplastic agent carmustine cause permanent changes in craniofacial growth of immature rats.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Body Weight; Carmustine; Case-Cont | 2002 |
[Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carmustine; Cell Cy | 2002 |
Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Carmustine; Crosses, Genetic; Dose-Response | 2005 |
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
Topics: Animals; Body Weight; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Fibrosarcoma; Leukocy | 1980 |
Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth.
Topics: Animals; Body Weight; Brain Neoplasms; Calmodulin; Carmustine; Cell Division; Chlorpromazine; Drug S | 1994 |
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Topics: Animals; Body Weight; Brain Neoplasms; Carmustine; Cell Division; Colonic Neoplasms; Drug Screening | 1994 |
Enhanced antitumor activity and reduced toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea administered in lipid microspheres to tumor-bearing mice.
Topics: Animals; Body Weight; Carmustine; Drug Delivery Systems; Leukemia L1210; Lipids; Male; Mice; Microsp | 1993 |
Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1993 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |
Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Carmustine; Cell Survival; Cells, Cultured | 1996 |
Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Carmustine; Cell Line; Con | 1997 |
Effect of spermine synthase deficiency on polyamine biosynthesis and content in mice and embryonic fibroblasts, and the sensitivity of fibroblasts to 1,3-bis-(2-chloroethyl)-N-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Brain; Carmustine; Cell Survival; Dose-Resp | 2000 |
Antitumor activity of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea (MeCCNU) on Yoshida sarcoma ascites cells implanted into the colon wall of rats.
Topics: Animals; Body Weight; Carmustine; Colonic Neoplasms; Cyclophosphamide; Male; Nitrosourea Compounds; | 1979 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Tissue and biliary glutathione disulfide in the perfused vitamin E-deficient rat liver.
Topics: Animals; Bile; Body Weight; Carmustine; Glutathione; Glutathione Peroxidase; In Vitro Techniques; Li | 1989 |
Cardiovascular performance in anesthetized rats pretreated with 1,3-bis(2-chloroethyl)-1-Nitrosourea (BCNU).
Topics: Anesthesia; Animals; Arterioles; Blood Pressure; Body Water; Body Weight; Carmustine; Collagen; Hear | 1989 |
Effects of sodium cyanate in mice bearing B16 melanoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmust | 1986 |
Reproduction and teratology studies with oncolytic agents in the rat and rabbit. I. I,3-bis(2-chloroethyl)-i-nitrosourea (BCNU).
Topics: Abnormalities, Drug-Induced; Analysis of Variance; Animals; Animals, Newborn; Birth Weight; Body Wei | 1974 |